Partnership forms for point-of-care pathogen detection device

The two companies will develop and market a novel pathogen detection system in the form of a point-of-care diagnostic instrument for veterinary use.

Veterinary diagnostic and pharmaceutical company Zomedica Pharmaceuticals (Ann Arbor, MI) has entered into a development, commercialization, and exclusive distribution agreement with human biomedical device company Seraph Biosciences (Detroit, MI). Under the terms of the agreement, Zomedica will have exclusive global veterinary industry rights to develop and market a novel pathogen detection system in the form of a point-of-care diagnostic instrument.

Related: Smartphone-driven lab-on-a-chip quickly detects multiple pathogens

Leveraging principles of Raman spectroscopy, the two companies are partnering to bring human diagnostic technology to veterinarians, beginning with the examination of urine and fecal samples. The ZM-020 diagnostic instrument is expected to deliver rapid results and an enhanced workflow with minimal sample preparation time. Zomedica’s development work will seek to expand the capabilities of in-clinic testing to include pathogen detection as well as genus- and species-level information.

The agreement with Seraph covers development and validation of the ZM-020 instrument. Zomedica will be responsible for development and validation, and their associated costs. Seraph will supply Zomedica, on an exclusive basis, with the hardware platform, associated software, and consumables to be developed under the agreement. Zomedica will be responsible for the marketing and sale of the hardware platform, associated software, and consumables. Marketing and sales are expected to begin in 2019, with an initial focus on canines and expanding into feline applications post-launch.

For more information, please visit seraspec.com and www.zomedica.com.

More in Biophotonics Tools